Physician profile
Dheera Grover
NPI 1578184719
$1,139.96
in general payments reported to CMS, 2019-2025
10 companies · $670 in 2025
The $670 reported for 2025 was more than what 92% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $470 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $950 · Education: $190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $949.93 |
| Education | $190.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $382.51 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $241.55 | 2024-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $124.83 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $98.44 | 2024-2025 | |
| Olympus America INC. | $87.02 | 2025 | Single Use Electrosurgical Knife Kd-655, Single Use Aspiration Needle Na-U200h, Endoclot Phs |
| Ardelyx, INC. | $63.96 | 2025 | Ibsrela |
| Ipsen Biopharmaceuticals, INC | $57.31 | 2024-2025 | Bylvay, Iqirvo |
| Steris Corporation | $34.19 | 2025 | |
| Glaxosmithkline, LLC. | $28.12 | 2024 | |
| Celltrion USA INC. | $22.03 | 2024 | Zymfentra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dheera Grover listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.